AusPAR: Ofatumumab
Australian Public Assessment Report
Device/Product Name
Kesimpta
Active ingredients
Ofatumumab
AusPAR Date
Published
Sponsor
Submission Number
PM-2020-00666-1-1
Submission Type
Extension of indications and major variation (new dosage form)
Decision
Approved